NDAORALFOR SOLUTIONPriority Review
Approved
Jan 2018
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
Priority Review
FIRVANQ KIT (vancomycin hydrochloride) by R-Pharm US is [ see microbiology ( ) ]. Approved for prosthetic joint infection. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIRVANQ KIT is an oral vancomycin hydrochloride formulation approved for treating prosthetic joint infections, a serious complication requiring targeted antimicrobial therapy. The drug works by inhibiting bacterial cell-wall biosynthesis while altering cell-membrane permeability and RNA synthesis, making it bactericidal against susceptible pathogens. This represents a formulation innovation in oral vancomycin delivery.
Peak8.9 years to LOE
Product is at peak revenue stage with established market presence; commercial teams likely focused on optimizing market penetration and defending against generic competition.
Mechanism of Action
[ see Microbiology ( ) ].
Career Relevance
Worked on FIRVANQ KIT at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.